NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Wednesday that its first quarter earnings fell 30 percent, driven by a sharp drop in laboratory services revenues.

For the three months ended March 31, the firm's revenues fell to $771,771 from $1.1 million in Q1 2016.

Product sales fell 22 percent to $734,502 from $947,219 a year ago, while laboratory services revenues fell 88 percent to $16,105 from $129,420. The company also recorded $21,164 in revenues from collaborations in Q1 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.